Hitting the target: Where do molecularly targeted therapies fit in the treatment scheduling of neuroendocrine tumours?

Endocrine-Related Cancer

Volumn 19, Issue 3, 2012, Pages

  Karpathakis, Anna ^a,b   Caplin, Martyn ^b   Thirlwell, Christina ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANGIOPEPTIN; AXITINIB; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; OXALIPLATIN; PAZOPANIB; PENTETREOTIDE IN 111; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; UNINDEXED DRUG; VASCULOTROPIN;

ANEMIA; ASTHENIA; BRONCHUS TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ASSESSMENT; COLORECTAL CARCINOMA; DIARRHEA; DYSESTHESIA; ERYTHEMA; FATIGUE; GENE TARGETING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; IMMUNOMODULATION; INTESTINE TUMOR; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREATIC NEUROENDOCRINE TUMOR; PATHOGENESIS; PATIENT SELECTION; PNEUMONIA; PRACTICE GUIDELINE; RASH; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BRONCHIAL NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS;

EID: 84862637269     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0050     Document Type: Review

References (100)

1. Akerstrom G, Hessman O, Hellman P & Skogseid B 2005 Pancreatic tumours as part of the MEN-1 syndrome. Best Practice & Research. Clinical Gastroenterology 19 819-830. (doi:10.1016/j.bpg.2005.05.006)
2. Allen E, Walters IB & Hanahan D 2011 Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clinical Cancer Research 17 5299-5310. (doi:10.1158/1078-0432.CCR-10-2847)
3. Anderson T, Schein PS, McMenamin MG & Cooney DA 1974 Streptozotocin diabetes. Correlation with extent of depression of pancreatic islet nicotinamide adenine dinucleotide. Journal of Clinical Investigation 54 672-677. (doi:10.1172/JCI107805)
4. Arnold R, Rinke A, Klose KJ, Müller HH, Wied M, Zamzow K, Schmidt C, Schade-Brittinger C, Barth P, Moll R et al. 2005 Octreotide versus octreotide plus interferon-α in endocrine gastroenteropancreatic tumors: a randomized trial. Clinical Gastroenterology and Hepatology 3 761-771. (doi:10.1016/S1542- 3565(05)00481-7)
5. di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N & di Leo A 1996 Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77 402-408. (doi:10.1002/(SICI)1097- 0142(19960115)77: 2!402::AID-CNCR25O3.0.CO;2-4)
6. Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY & Bentrem DJ 2008 Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Annals of Surgery 247 490-500. (doi:10.1097/SLA. 0b013e31815b9cae)
7. Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, Seidel G, Shutack Y, Yuldasheva N, Eugeni M et al. 2007 Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 142 814-818 (discussion 818.e1-2). (doi:10.1016/j.surg.2007.09.012)
8. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A et al. 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism 86 5658-5671. (doi:10.1210/jc.86.12.5658)
9. 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumors. Journal of Nuclear Medicine 44 1-6.
10. Calender A 2006 Genetics of neuroendocrine tumours. In Handbook of Neuroendocrine Tumours, pp 53-81. Eds, M Caplin & L Kvols. BioScientifica Ltd: Bristol, UK.
11. Cantley LC 2002 The phosphoinositide 3-kinase pathway. Science 296 1655-1657. (doi:10.1126/science.296.5573. 1655)
12. Chan JA, Mayer RJ, Jackson N, Malinowski P, Regan E &Kulke M 2010 Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors (NET). ASCO Meeting Abstracts. Journal of Clinical Oncology 28 (15-suppl) e14597.
13. Chiu CW, Nozawa H & Hanahan D 2010 Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. Journal of Clinical Oncology 28 4425-4433. (doi:10.1200/JCO.2010.28.0198)
14. Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K et al. 2005 Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. British Journal of Cancer 92 94-101. (doi:10.1038/sj.bjc.6602245)
15. Couvelard A, Deschamps L, Rebours V, Sauvanet A, Gatter K, Pezzella F, Ruszniewski P & Bedossa P 2008 Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH is associated with tumor aggressiveness in pancreatic endocrine tumors. Clinical Cancer Research 14 6634-6639. (doi:10.1158/1078-0432. CCR-07-5258)
16. Cwikla JB, Sankowski A, Seklecka N, Buscombe JR, Nasierowska-Guttmejer A, Jeziorski KG, Mikolajczak R, Pawlak D, Stepien K, Walecki J et al. 2010 Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Annals of Oncology 21 787-794. (doi:10.1093/annonc/ mdp372)
17. Delaunoit T, Ducreux M, Boige V, Dromain C, Sabourin JC, Duvillard P, Schlumberger M, de Baere T, Rougier P, Ruffie P et al. 2004 The doxorubicin-streptozotocin combination for the treatment of advanced welldifferentiated pancreatic endocrine carcinoma; a judicious option? European Journal of Cancer 40 515-520. (doi:10.1016/j.ejca.2003.09.035)
18. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M et al. 2007 Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clinical Cancer Research 13 2986-2991. (doi:10.1158/1078-0432.CCR-06-2053)
19. Engstrom PF, Lavin PT, Moertel CG, Folsch E &Douglass HO Jr 1984 Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. Journal of Clinical Oncology 2 1255-1259. (Pubitemid 15202700)
20. Eriksson B, Annibale B, Bajetta E, Mitry E, Pavel M, Platania M, Salazar R, Plöckinger U & Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society 2009 ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 90 214-219. (doi:10.1159/000225950)
21. Faiss S, Scherübl H, Riecken EO & Wiedenmann B 1996 Interferon-α versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours. Digestion 57 (Suppl 1) 84-85. (doi:10.1159/000201404)
22. Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B & International Lanreotide and Interferon Alfa Study Group 2003 Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. Journal of Clinical Oncology 21 2689-2696. (doi:10.1200/JCO.2003.12.142)
23. Faivre S, Demetri G, Sargent W & Raymond E 2007 Molecular basis for sunitinib efficacy and future clinical development. Nature Reviews. Drug Discovery 6 734-745. (doi:10.1038/nrd2380)
24. Faivre S, Sablin MP, Dreyer C & Raymond E 2010 Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America 39 811-826. (doi:10.1016/j.ecl. 2010.09.006)
25. Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O'Connor JM, Salazar R, Taal BG, Vullierme MP, O'Toole D et al. 2011 ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system.Well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 95 120-134. (doi:10.1159/000335587)
26. Goldstein R &Meyer T 2011 Role of everolimus in pancreatic neuroendocrine tumors. Expert Review of Anticancer Therapy 11 1653-1665. (doi:10.1586/era.11.145)
27. Granberg D, Eriksson B, Wilander E, Grimfjärd P, Fjällskog M-L, Ö berg K & Skogseid B 2001 Experience in treatment of metastatic pulmonary carcinoid tumors. Annals of Oncology 12 1383-1391. (doi:10.1023/ A:1012569909313)
28. Grozinsky-Glasberg S, Kaltsas G, Gur C, Gal E, Thomas D, Fichman S, Alexandraki K, Barak D, Glaser B, Shimon I et al. 2008a Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. European Journal of Endocrinology 159 475-482. (doi:10.1530/EJE-08-0420)
29. Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A Jr, Dalino P, Salahuddin N, Korbonits M & Grossman AB 2008b Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 87 168-181. (doi:10.1159/000111501)
30. Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM, Chauveau D, Balian A, Beigelman C, O'Toole D et al. 2000 Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology 119 1087-1095. (doi:10.1053/gast.2000.18143)
31. Hicklin DJ & Ellis LM 2005 Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology 23 1011-1027. (doi:10.1200/JCO.2005.06.081)
32. Hobday TJ, Rubin J, Holen K, Picus J, Donehower R, Marschke R, Maples W, Lloyd R, Mahoney M &Erlichman C 2007 MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. ASCO Meeting Abstracts. Journal of Clinical Oncology 25 (18-suppl) 4504.
33. Hofland LJ, de Herder WW, Waaijers M, Zuijderwijk J, Uitterlinden P, van Koetsveld PM & Lamberts SW 1999 Interferon-α-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 84 3336-3343. (doi:10.1210/jc.84.9.3336)
34. Huang J & Manning BD 2008 The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochemical Journal 412 179-190. (doi:10.1042/ BJ20080281)
35. 90Y-DOTA]-TOC in metastasized neuroendocrine cancers. Journal of Clinical Oncology 29 2416-2423. (doi:10.1200/JCO.2010.33.7873)
36. Isacoff WH, Moss RA, Pecora AL & Fine RL 2006 Temozolomide/ capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review. ASCO Meeting Abstracts. Journal of Clinical Oncology 24 (18-suppl) 14023.
37. Jessen K, Wang S, Kessler L, Guo X, Kucharski J, Staunton J, Lan L, Elia M, Stewart J, Brown J et al. 2009 Abstract B148: INK128 is a potent and selective TORC1/2 inhibitor with broad oral antitumor activity. Molecular Cancer Therapeutics 8 (Suppl 1) B148.
38. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA et al. 2011 DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331 1199-1203. (doi:10.1126/science. 1200609)
39. Johannessen CM, Reczek EE, James MF, Brems H, Legius E & Cichowski K 2005 The NF1 tumor suppressor critically regulates TSC2 and mTOR. PNAS 102 8573-8578. (doi:10.1073/pnas.0503224102)
40. Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M & Knox JJ 2009 Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 94 5-9. (doi:10.1210/jc.2008-1836)
41. Karar J & Maity A 2011 PI3K/AKT/mTOR pathway in angiogenesis. Frontiers in Molecular Neuroscience 4 51. (doi:10.3389/fnmol.2011.00051)
42. Khan MS & Caplin ME 2011 Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer 18 (Suppl 1) S53-S74. (doi:10.1530/ERC-10-0271)
43. Khan MS, Tsigani T, Rashid M, Rabouhans JS, Yu D, Luong TV, Caplin M & Meyer T 2011 Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clinical Cancer Research 17 337-345. (doi:10.1158/ 1078-0432.CCR-10-1776)
44. Kolby L, Persson G, Franzén S & Ahrén B 2003 Randomized clinical trial of the effect of interferon α on survival in patients with disseminated midgut carcinoid tumours. British Journal of Surgery 90 687-693. (doi:10.1002/bjs. 4149)
45. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R & Yao JC 2004 Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. Journal of Clinical Oncology 22 4762-4771. (doi:10.1200/JCO.2004.04.024)
46. 123I-Tyr3]- octreotide: the Rotterdam experience with more than 1000 patients. European Journal of Nuclear Medicine 20 716-731. (doi:10.1007/BF00181765)
47. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A & Fuchs CS 2006 Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. Journal of Clinical Oncology 24 401-406. (doi:10.1200/ JCO.2005.03.6046)
48. Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS et al. 2009 O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clinical Cancer Research 15 338-345. (doi:10.1158/1078-0432.CCR-08-1476)
49. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC et al. 2010 NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39 735-752. (doi:10.1097/MPA.0b013e3181ebb168)
50. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ et al. 2011 Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. Journal of Clinical Oncology 29 934-943. (doi:10.1200/ JCO.2010.33.2056)
51. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J &Hahn RG 1986 Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. New England Journal of Medicine 315 663-666. (doi:10.1056/NEJM198609113151102)
52. 177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology 26 2124-2130. (doi:10.1200/JCO.2007.15.2553)
53. Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudła B, de Herder WW, Plöckinger U & Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society 2009 ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 90 220-226. (doi:10.1159/000225951)
54. Lott ST, Chandler DS, Curley SA, Foster CJ, El-Naggar A, Frazier M, Strong LC, Lovell M & Killary AM 2002 High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumors: evidence for a stepwise mechanism for malignant conversion in VHL tumorigenesis. Cancer Research 62 1952-1955.
55. Marx SJ 2005 Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nature Reviews. Cancer 5 367-375. (doi:10.1038/nrc1610)
56. Maton PN, Gardner JD & Jensen RT 1989 Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Digestive Diseases and Sciences 34 (3 suppl) 28S-39S. (doi:10.1007/ BF01536043)
57. Mendivil A, Zhou C, Cantrell LA, Gehrig PA, Malloy KM, Blok LJ, Burger CW & Bae-Jump VL 2011 AMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathways. Reproductive Sciences 18 832-841. (doi:10.1177/1933719111398501)
58. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G et al. 2010 Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. Journal of Clinical Oncology 28 245-255. (doi:10.1200/JCO.2008.21.5988)
59. Moertel CG, Hanley JA & Johnson LA 1980 Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine 303 1189-1194. (doi:10.1056/ NEJM198011203032101)
60. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG &Klaassen D 1992 Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine 326 519-523. (doi:10.1056/NEJM199202203260804)
61. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC &Meric-Bernstam F 2008 Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocrine-Related Cancer 15 257-266. (doi:10.1677/ERC-07-0202)
62. Oberg K, Funa K & Alm G 1983 Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. New England Journal of Medicine 309 129-133. (doi:10.1056/NEJM198307213090301)
63. Oberg K, Ferone D, Kaltsas G, Knigge UP, Taal B, Plöckinger U & Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society 2009 ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. Neuroendocrinology 90 209-213. (doi:10.1159/000183751)
64. Oberg K, Hellman P, Kwekkeboom D, Jelic S & ESMO Guidelines Working Group 2010a Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21 (Suppl 5) v220-v222. (doi:10.1093/annonc/mdq191)
65. Oberg K, Akerström G, Rindi G, Jelic S & ESMO Guidelines Working Group 2010b Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21 (Suppl 5) v223-v227. (doi:10.1093/annonc/mdq192)
66. O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, BouchéO, Catus F, Blumberg J & Ruszniewski P 2000 Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 88 770-776. (doi:10.1002/(SICI)1097-0142(20000215)88:4〈770:: AID-CNCR6〉3.0.CO;2-0)
67. Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, Arnold R, Denecke T, Plöckinger U, Salazar R et al. 2011 ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 95 135-156. (doi:10.1159/000335629)
68. Parmar S & Platanias LC 2005 Interferons. Cancer Treatment and Research 126 45-68.
69. Pavel M, Baudin E, Couvelard A, Krenning E, Ö berg K, Steinmü ller T, Anlauf M, Wiedenmann B, Salazar R &Barcelona Consensus Conference participants 2011a ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95 157-176. (doi:10.1159/000335597)
70. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM et al. 2011b Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378 2005-2012. (doi:10.1016/S0140- 6736(11)61742-X)
71. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V et al. 2012 Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 61 6-32. (doi:10.1136/gutjnl-2011-300831)
72. Raymond E, Faivre S, Hammel P & Ruszniewski P 2009 Sunitinib paves the way for targeted therapies in neuroendocrine tumors. Targeted Oncology 4 253-254. (doi:10.1007/s11523-009-0130-0)
73. Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A et al. 2011a Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine 364 501-513. (doi:10.1056/ NEJMoa1003825)
74. Raymond E, Hobday T, Castellano D, Reidy-Lagunes D, García- Carbonero R & Carrato A 2011b Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Reviews 30 (Suppl 1) 19-26.
75. Rickman OB, Vohra PK, Sanyal B, Vrana JA, Aubry MC, Wigle DA & Thomas CF Jr 2009 Analysis of ErbB receptors in pulmonary carcinoid tumors. Clinical Cancer Research 15 3315-3324. (doi:10.1158/1078-0432.CCR-08-2549)
76. Rinke A, Müller H-H, Schade-Brittinger C, Klose K-J, Barth P, Wied M, Mayer C, Aminossadati B, Pape U-F, Bläker M et al. 2009 Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology 27 4656-4663. (doi:10.1200/JCO.2009.22.8510)
77. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P & Anthony L 1999 Octreotide acetate long-acting formulation versus openlabel subcutaneous octreotide acetate inmalignant carcinoid syndrome. Journal of Clinical Oncology 17 600-606. (Pubitemid 29075248)
78. Ruszniewski P, Ducreux M, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R et al. 1996 Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 39 279-283. (doi:10.1136/gut.39.2.279)
79. Schmitt AM, Schmid S, Rudolph T, Anlauf M, Prinz C, Klöppel G, Moch H, Heitz PU, Komminoth P & Perren A 2009 VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocrine-Related Cancer 16 1219-1227. (doi:10.1677/ERC-08-0297)
80. Semenza GL 2003 Targeting HIF-1 for cancer therapy. Nature Reviews. Cancer 3 721-732. (doi:10.1038/nrc1187)
81. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP &Caplin ME 2006 Epidermal growth factor receptor expression and activation in neuroendocrine tumours. Journal of Neuroendocrinology 18 355-360. (doi:10.1111/j.1365-2826. 2006.01425.x)
82. Shaw RJ & Cantley LC 2006 Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 424-430. (doi:10.1038/nature04869)
83. Srirajaskanthan R, Toumpanakis C, Karpathakis A, Marelli L, Quigley AM, Dusmet M, Meyer T & Caplin ME 2009 Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients. Lung Cancer 65 68-73. (doi:10.1016/j.lungcan.2008.10.025)
84. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J & Kvols L 2011a First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117 268-275. (doi:10.1002/cncr.25425)
85. Strosberg JR, Cheema A & Kvols LK 2011b A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control 18 127-137.
86. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG &Eastern Cooperative Oncology Group 2005 Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. Journal of Clinical Oncology 23 4897-4904. (doi:10.1200/JCO.2005.03.616)
87. Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R & Gullo L 2000 Treatment of type II gastric carcinoid tumors with somatostatin analogues. New England Journal of Medicine 343 551-554. (doi:10.1056/ NEJM200008243430805)
88. Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C et al. 2010 Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. British Journal of Cancer 102 1106-1112. (doi:10.1038/sj.bjc.6605618)
89. Villaume K, Blanc M, Gouysse G, Walter T, Couderc C, Nejjari M, Vercherat C, Cordier-Bussat M, Roche C &Scoazec JY 2010 VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway. Neuroendocrinology 91 268-278. (doi:10.1159/000289569)
90. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G &Riva P 2002 In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Seminars in Nuclear Medicine 32 148-155. (doi:10.1053/snuc.2002.31565)
91. Watanabe R, Wei L & Huang J 2011 mTOR signaling, function, novel inhibitors, and therapeutic targets. Journal of Nuclear Medicine 52 497-500.
92. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G &Seufferlein T 2000 Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Research 60 4573-4581. (Pubitemid 32103642)
93. Wulbrand U, Remmert G, Zöfel P, Wied M, Arnold R &Fehmann HC 2000 mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. European Journal of Clinical Investigation 30 729-739. (doi:10.1046/j.1365-2362.2000.00700.x)
94. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B et al. 2011 Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Molecular Cancer Therapeutics 10 2298-2308. (doi:10.1158/1535-7163.MCT-11-0264)
95. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey J-N, Rashid A et al. 2008a One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology 26 3063-3072. (doi:10.1200/JCO.2007.15.4377)
96. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL & Ajani JA 2008b Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon a-2b. Journal of Clinical Oncology 26 1316-1323. (doi:10.1200/JCO.2007.13.6374)
97. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EGE et al. 2011 Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 364 514-523. (doi:10.1056/NEJMoa1009290)
98. Zatelli MC, Minoia M, Martini C, Tagliati F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E, Cavallesco G et al. 2010 Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocrine-Related Cancer 17 719-729. (doi:10.1677/ERC-10-0097)
99. Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey JN, Xie K & Yao JC 2007 Elevated expression of vascular endothelial growth factor correlateswith increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109 1478-1486. (doi:10.1002/cncr.22554)
100. Zitzmann K, Rüden J, Brand S, Göke B, Lichtl J, Spöttl G &Auernhammer CJ 2010 Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Letters 295 100-109. (doi:10.1016/j.canlet. 2010.02.018)